On Monday, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced that they have submitted an Emergency Use Authorization (EUA) request to the U.S. Food and Drug Administration (FDA) for a 10 -µg booster dose of its Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The companies also stated that they intend to submit an application seeking an extension of marketing authorization for the Omicron BA.4/BA.5-adapted bivalent vaccine targeting children ages 5 through 11 years to the European Medicines Agency (EMA).